SCiF
SICKLE CELL IN FOCUS
LONDON • WASHINGTON

# PROGRAMME

FREE REGISTRATION OPEN NOW

Want to be kept updated?

Follow us on Twitter
@STSTNetwork

Subscribe via email
info@ststn.co.uk

Details on how to register and for more information please visit:
www.ststn.co.uk/scif/scif2016/

# THE 10TH SICKLE CELL IN FOCUS CONFERENCE

2 - 3 JUNE 2016

## Natcher Conference Center
National Heart, Lung and Blood Institute (NHLBI)
National Institutes of Health (NIH)
Bethesda, near Washington DC, USA

Co-hosted by the National Heart, Lung and Blood Institute and the South Thames Sickle Cell & Thalassaemia Network, this two-day, intensive, educational conference highlights and discusses emerging clinical complications and management of sickle cell disease.

The clinical and scientific lectures are aimed at consultants, trainee doctors, healthcare professionals involved in the care of patients with sickle cell disease, plus academic researchers in this field.

www.ststn.co.uk/scif/scif2016/

NIH National Heart, Lung, and Blood Institute

South Thames Sickle Cell & Thalassaemia Network

KING'S HEALTH PARTNERS
Pioneering better health for all

## SESSION ONE: SICKLE CELL DISEASE - A GLOBAL HEALTH ISSUE

United States of America:
Kathy Hassell
University of Colorado, USA

Europe:
Beatrice Gulbis
Hôpital Erasme, Belgium

Africa:
Dapa Diallo
University of Bamako, Mali

The Caribbean:
Jennifer Knight
University Hospital of the West Indies, Jamaica

Brazil:
Anna Proietti
Hemominas Foundation, Brazil

India:
Roshan B. Colah
National Institute of Immunohaematology, India

## SESSION TWO: SICKLE CELL DISEASE AND MALARIA - MORE THAN JUST A BALANCING ACT

Protective role of HbS and other red blood cell defects on malaria:
Tom Williams
Imperial College London, UK \ KEMRI-Wellcome Trust Collaborative Programme, Kilifi, Kenya

Adhesion, occlusion, and tissue perfusion in malaria and sickle cell disease:
Hans Ackerman
National Heart, Lung and Blood Institute, National Institutes of Health, USA

A microfluidic platform to assess malaria and sickle stickiness:
Subra Suresh
Carnegi Mellon University, Pittsburgh, USA

## SESSION THREE: VASCULAR INJURY & INFLAMMATION IN SICKLE CELL DISEASE

Inflammasomes in health and disease:
Fayyaz Sutterwala
University of Iowa, USA

Drivers of inflammation in sickle cell disease - role of TLR:
John Belcher
University of Minnesota, USA

Drivers of inflammation in sickle cell disease - role of neutrophils:
Dachuan Zhang
Albert Einstein College of Medicine, USA

## SESSION FOUR: UPDATES

Newborn screening and point-of-care testing in developing countries:
Carolyn Hoppe
Children's Hospital & Research Center, USA

Clinical trials:
Deepa Manwani
The Children's Hospital at Montefiore, USA

Bone marrow transplant:
John Horan
Children's Healthcare of Atlanta, USA

## SESSION FIVE: DEBATE
## HSCT IS RECOMMENDED FOR SECONDARY PREVENTION OF CEREBROVASCULAR INFARCTS IN SICKLE CELL DISEASE

For:
Michael DeBaun
Vanderbilt University School of Medicine, USA

Against:
Elliott Vichinsky
Children's Hospital & Research Center, Oakland, USA

## SESSION ONE: GENETICS & GENOMICS - PRIME TIME IN HEMOGLOBIN DISORDERS

Genetics and genomics in clinical studies –potentials and pitfalls:
Steve Chanock
National Cancer Institute, National Institutes of Health, USA

Impact of genetics and genomics in sickle cell disease:
Swee Lay Thein
National Heart, Lung and Blood Institute, National Institutes of Health, USA

Gene therapy:
John Tisdale
National Heart, Lung and Blood Institute, National Institutes of Health, USA

Application of genome editing in hemoglobin disorders:
Dan Bauer
Children's Hospital Boston, USA

Environmental determinants of disease severity:
David Rees
King's College Hospital NHS Foundation Trust / King's College London, UK

## SESSION TWO: UPDATES ON MANAGEMENT - PART ONE

Management of pain and opioid use in patients with sickle cell disease:
Patrick Carroll
Johns Hopkins University School of Medicine, USA

Inflammation and pain in sickle cell disease:
Deepika Darbari
Children's National Medical Center, USA

Causes, complications and management of hypoxia in sickle cell disease:
Roberto Machado
University of Illinois College of Medicine at Chicago, USA

## SESSION THREE : UPDATES ON MANAGEMENT - PART TWO

Expanding use of hydroxyurea in sickle cell disease:
Jane Hankins
St Jude Children's Research Hospital, USA

Blood transfusion, alloimmunisation and the role of variant genotyping:
Stella Chou
The Children's Hospital of Philadelphia, USA

VTEs in sickle cell disease:
Kenneth Ataga
University of North Carolina, USA

## SESSION FOUR: DEBATE
## HIGH MORTALITY IN YOUNG ADULTS IS DUE TO THE BREAKDOWN IN TRANSITION TO ADULT CARE

Yes:
Mariane de Montalembert
Necker-Enfants Malades Hospital, France

No:
Sophie Lanzkron
Johns Hopkins University School of Medicine, Baltimore, USA